Table 1. Prognostic factors for survival by treatment arm and primary site.
Control (%)
|
Efaproxiral (%)
|
||||||
---|---|---|---|---|---|---|---|
Prognostic factor | Level | All (N=250) | NSCLC (N=145) | Breast (N=49) | All (N=265) | NSCLC (N=146) | Breast (N=58) |
RPA Class | I | 10 | 10 | 8 | 11 | 10 | 14 |
II | 90 | 90 | 92 | 89 | 90 | 86 | |
Primary tumour control | Yes | 24 | 21 | 31 | 26 | 19 | 33 |
No | 76 | 79 | 69 | 74 | 81 | 67 | |
Age | <65 years | 73 | 69 | 80 | 72 | 69 | 79 |
⩾65 years | 27 | 31 | 20 | 28 | 31 | 21 | |
Extra-cranial metastases | Yes | 64 | 55 | 88 | 69 | 54 | 88 |
No | 36 | 45 | 12 | 31 | 46 | 12 | |
KPS | <90 | 47 | 44 | 47 | 40 | 41 | 38 |
90–100 | 53 | 56 | 53 | 59 | 58 | 62 | |
Number of brain lesions | 1 | 20 | 26 | 8 | 17 | 17 | 21 |
2–3 | 32 | 34 | 18 | 30 | 36 | 22 | |
>3 | 47 | 40 | 73 | 52 | 46 | 57 |
NSCLC=non-small-cell lung cancer; RPA=recursive partitioning analysis; KPS=karnofsky performance status.